Arch works closely with the scientific community, universities and research institutions to advance and build the value of select medical innovations, develop the most promising intellectual property, and create value for its investors.
The company holds a strong patent portfolio of new drug candidates to prevent inflammation and organ injury.
Arch’s Phase I and Phase II clinical trials led to LSALT peptide (Metablok), being the first novel therapeutic to join the Canadian Treatments for COVID-19 trial, a multi-centre adaptive, randomized, open-label, controlled clinical trial involving fifty-five hospitals across Canada.
• Arch scientists described a novel mechanism of action for organ inflammation in the journal Cell.
• Arch scientists identified the enzyme dipeptidase-1 (DPEP1) as a major neutrophil (white blood cell) adhesion receptor in the lungs, kidneys and liver.
• DPEP1 was shown to be the target of LSALT peptide (Metablok), the Company’s lead drug candidate targeting inflammation in the lungs and kidneys.
Arch is currently working to advance LSALT peptide through the production of additional human safety and efficacy data in a Phase II trial to prevent IRI-acute kidney injury (AKI).
Please follow the company on LinkedIn, and subscribe at the website for the latest science and investor news.
Company Details
- Employees
- 7
- Founded
- -
- Address
- 27 St. Clair Ave East, Po Box 305,canada
- Phone
- (647) 428–7031
- in****@****ers.com
- Industry
- Biotechnology
- Website
- archbiopartners.com
- Keywords
- Treating Acute Kidney Injury, Treatments for Inflammation, Sepsis, Acute Organ Inflammation, Novel Therapeutics.
- HQ
- Toronto, ON
Arch Biopartners Inc (Arch:tsxv) (Achff:otcqb) Questions
Arch Biopartners Inc (Arch:Tsxv) (Achff:Otcqb)'s helpline number is (647) 428–7031
Arch Biopartners Inc (Arch:Tsxv) (Achff:Otcqb)'s website is archbiopartners.com
Arch Biopartners Inc (Arch:Tsxv) (Achff:Otcqb)'s LinkedIn profile is https://ca.linkedin.com/company/arch-biopartners-inc-foiff-
Arch Biopartners Inc (Arch:Tsxv) (Achff:Otcqb) has
7 employees.
View email and phone details for 7
employees at Arch Biopartners Inc (Arch:Tsxv) (Achff:Otcqb).
Arch Biopartners Inc (Arch:Tsxv) (Achff:Otcqb)'s industry is
Biotechnology
Arch Biopartners Inc (Arch:Tsxv) (Achff:Otcqb)'s top competitors are
Proteocyte Ai,
Edesa Biotech, Inc.,
Pharmala Biotech Inc. (Mdma.cse),
Vimy Pharma,
Telara Pharma,
Anogen-W.x. Lifeantibody Solution Ltd.,
Mediphage,
Spindle Biotech Inc.,
Dri Healthcare,
Cardiol Therapeutics Inc..
Arch Biopartners Inc (Arch:Tsxv) (Achff:Otcqb)'s support email address is info@archbiopartners.com
Arch Biopartners Inc (Arch:Tsxv) (Achff:Otcqb)'s categories are Biotechnology
Arch Biopartners Inc (Arch:Tsxv) (Achff:Otcqb)'s founding year is 2010
